<?xml version="1.0"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><atom:link href="http://www.cnbc.com/id/10000108/device/rss/rss.html" rel="self" type="application/rss+xml" /><title>Health Care</title><description><![CDATA[Healthcare]]></description><link>http://www.cnbc.com/id/10000108</link><pubDate>Wed, 13 Feb 2013 17:22 GMT</pubDate><lastBuildDate>Wed, 13 Feb 2013 17:22 GMT</lastBuildDate><language>en-us</language><ttl>60</ttl><item><title>XenoPort: Horizant likely available in early June</title><description><![CDATA[SANTA CLARA, Calif.-- Drug developer XenoPort said Friday that its treatment for restless leg syndrome, Horizant, will likely be available to U.S. patients in early June. Last month XenoPort Inc. said that there was a shortage of Horizant, with patients telling them that they were unable to fill prescriptions.]]></description><link>http://www.cnbc.com/id/100746448</link><pubDate>Fri, 17 May 2013 14:52 GMT</pubDate><guid isPermaLink="false">guid_100746448</guid> </item>  <item><title>Oncothyreon slumps on new cancer drug data</title><description><![CDATA[NEW YORK-- Shares of Oncothyreon Inc. fell Thursday after the drug developer announced new clinical trial data about an experimental lung cancer treatment that failed to improve overall survival rate. THE SPARK: Oncothyreon said that it identified some patients who appeared to live longer after treatment with Stimuvax.]]></description><link>http://www.cnbc.com/id/100743597</link><pubDate>Thu, 16 May 2013 15:54 GMT</pubDate><guid isPermaLink="false">guid_100743597</guid> </item>  <item><title>More Than a Fat Paycheck: Jobs With Obese Workers </title><description><![CDATA[Does this job make me look fat? A Gallup-Healthways survey takes a look at which jobs have high rates of obesity.]]></description><link>http://www.cnbc.com/id/100743271</link><pubDate>Thu, 16 May 2013 14:52 GMT</pubDate><guid isPermaLink="false">guid_100743271</guid> </item>  <item><title>Health Care Industry Game Changers</title><description><![CDATA[CNBC&#039;s Julia Boorstin reports on companies that are looking to increase efficiency and implement simplicity in medical care. And, Grant Verstandig,  Audax Health founder and CEO, discusses how his digital health care startup encourages consumers to make healthier lifestyle choices.]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000168697</link><pubDate>Thu, 16 May 2013 12:14 GMT</pubDate><guid isPermaLink="false">guid_100742779</guid> </item>  <item><title>FDA approves Roche diagnostic for gene mutation in lung cancer</title><description><![CDATA[This marks the first companion diagnostic that detects epidermal growth factor receptor gene mutations to be approved by the U.S. Food and Drug Administration, the agency said.]]></description><link>http://www.cnbc.com/id/100736984</link><pubDate>Tue, 14 May 2013 20:53 GMT</pubDate><guid isPermaLink="false">guid_100736984</guid> </item>  <item><title>More Women Choosing Preventive Mastectomies</title><description><![CDATA[The number of women having preventive mastectomies has risen in recent years, but doctors say they have other options.]]></description><link>http://www.cnbc.com/id/100736370</link><pubDate>Tue, 14 May 2013 19:34 GMT</pubDate><guid isPermaLink="false">guid_100736370</guid> </item>  <item><title>Hospira's former chief scientific officer returns</title><description><![CDATA[LAKE FOREST, Ill.-- Drug and medical device maker Hospira Inc. said Tuesday that Dr.]]></description><link>http://www.cnbc.com/id/100736207</link><pubDate>Tue, 14 May 2013 17:16 GMT</pubDate><guid isPermaLink="false">guid_100736207</guid> </item>  <item><title>FDA approves labels with lower doses for zolpidem sleep drugs</title><description><![CDATA[The FDA in January asked zolpidem manufacturers, including NovaDel Pharma Inc and Swedish drugmaker Meda, to reduce recommended dosages on the drugs&#039; labels. The FDA recommended doses of 5 mg for women and either 5 mg or 10 mg for men for immediate-release zolpidem products such as Sanofi&#039;s Ambien.]]></description><link>http://www.cnbc.com/id/100735911</link><pubDate>Tue, 14 May 2013 15:54 GMT</pubDate><guid isPermaLink="false">guid_100735911</guid> </item>  <item><title>FDA accepts Seattle Genetics Adcetris application</title><description><![CDATA[BOTHELL, Wash.-- Drug developer Seattle Genetics Inc. said Tuesday the Food and Drug Administration has accepted its application to market the lymphatic cancer treatment Adcetris for some additional uses. Seattle Genetics expects the FDA to make a decision by Sept. 14.]]></description><link>http://www.cnbc.com/id/100735552</link><pubDate>Tue, 14 May 2013 14:29 GMT</pubDate><guid isPermaLink="false">guid_100735552</guid> </item>  <item><title>Hospitals could lose $500M in federal funds</title><description><![CDATA[MIAMI-- Hospitals nationwide could lose half a billion dollars in federal funding for uninsured patients next year under the national health overhaul _ a loss that will hit especially hard in states that decided against expanding Medicaid coverage.]]></description><link>http://www.cnbc.com/id/100735150</link><pubDate>Tue, 14 May 2013 13:04 GMT</pubDate><guid isPermaLink="false">guid_100735150</guid> </item>  <item><title>PDI moves to 1Q profit, revenue up 36 percent</title><description><![CDATA[NEW YORK-- PDI Inc., which provides sales and marketing services to the biopharmaceutical industry, said Monday that it turned a profit in the first quarter. Net income was $2.1 million, or 14 cents per share. The company had a loss of $272,000, or 2 cents per share, a year ago.]]></description><link>http://www.cnbc.com/id/100733075</link><pubDate>Mon, 13 May 2013 21:08 GMT</pubDate><guid isPermaLink="false">guid_100733075</guid> </item>  <item><title>UPDATE 2-Ranbaxy pleads guilty, to pay $500 mln in US settlement</title><description><![CDATA[*Ranbaxy says money set aside sufficient to cover costs. May 13- Indian generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the U.S. Department of Justice.]]></description><link>http://www.cnbc.com/id/100732543</link><pubDate>Mon, 13 May 2013 18:06 GMT</pubDate><guid isPermaLink="false">guid_100732543</guid> </item>  <item><title>Drugs Costs Face Vast Disparity Under Obamacare</title><description><![CDATA[Where you live could make a huge difference in what you&#039;ll pay for medications under Obamacare.]]></description><link>http://www.cnbc.com/id/100731024</link><pubDate>Mon, 13 May 2013 12:23 GMT</pubDate><guid isPermaLink="false">guid_100731024</guid> </item>  <item><title>UPDATE 3-Elan's $1 bln drug royalty deal aids bid defence</title><description><![CDATA[DUBLIN, May 13- Irish drugmaker Elan Corporation has agreed a $1 billion royalties deal that could soothe concerns about its potentially risky acquisition strategy and fend off a takeover bid from Royalty Pharma.]]></description><link>http://www.cnbc.com/id/100731231</link><pubDate>Mon, 13 May 2013 12:15 GMT</pubDate><guid isPermaLink="false">guid_100731231</guid> </item>  <item><title>UPDATE 1-U.S. FDA approves Glaxo/Theravance drug for COPD lung disease</title><description><![CDATA[May 10- The U.S. Food and Drug Administration has approved a new drug to treat chronic obstructive pulmonary disease, a condition often associated with smoking that can include emphysema, chronic bronchitis, or both. The drug, Breo, is an inhaled treatment made by British drugmaker GlaxoSmithKline Plc and Theravance Inc of the United States.]]></description><link>http://www.cnbc.com/id/100727563</link><pubDate>Fri, 10 May 2013 15:35 GMT</pubDate><guid isPermaLink="false">guid_100727563</guid> </item>  <item><title>NYC wins $70M from 44 pharmaceutical companies</title><description><![CDATA[NEW YORK-- New York City has won nearly $70 million from 44 pharmaceutical companies in a Medicaid fraud lawsuit over the pricing of prescription drugs. The New York City Law Department said Thursday that the city has already been paid about $60 million with the last settlements being processed.]]></description><link>http://www.cnbc.com/id/100727443</link><pubDate>Fri, 10 May 2013 14:57 GMT</pubDate><guid isPermaLink="false">guid_100727443</guid> </item>  <item><title>Intuitive Surgical Issues Urgent Notification</title><description><![CDATA[The maker of the da Vinci surgical robot has flagged a potential issue, reports CNBC&#039;s Herb Greenberg.]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000167613</link><pubDate>Fri, 10 May 2013 14:25 GMT</pubDate><guid isPermaLink="false">guid_100727430</guid> </item>  <item><title>Execs' Cushy Health Insurance May Trigger Fines</title><description><![CDATA[Employers offering plusher health benefits to higher-ups may be fined $100 a day for each worker who doesn&#039;t get the perk.]]></description><link>http://www.cnbc.com/id/100723962</link><pubDate>Thu, 09 May 2013 15:37 GMT</pubDate><guid isPermaLink="false">guid_100723962</guid> </item>  <item><title>Break Out the Bandages, Santelli's Tackling ObamaCare</title><description><![CDATA[CNBC&#039;s Rick Santelli maps out the problems he sees with the Patient Protection and Affordable Care Act.]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000167303</link><pubDate>Thu, 09 May 2013 14:52 GMT</pubDate><guid isPermaLink="false">guid_100724131</guid> </item>  <item><title>Drug Spending Drops for the First Time in 55 Years</title><description><![CDATA[Drug patent expirations resulted in less spending on medicines in the U.S. for the first time in at least 55 years.]]></description><link>http://www.cnbc.com/id/100723330</link><pubDate>Thu, 09 May 2013 12:31 GMT</pubDate><guid isPermaLink="false">guid_100723330</guid> </item>  <item><title>U.S. lawmakers advance bill on prescription drug tracking</title><description><![CDATA[WASHINGTON, May 8- A U.S. House of Representatives panel advanced a bill on Wednesday on how the federal government should track prescription drugs as they move through the distribution chain, over the objections of some Democrats who said the proposal did not go far enough to ensure safety.]]></description><link>http://www.cnbc.com/id/100721464</link><pubDate>Wed, 08 May 2013 20:40 GMT</pubDate><guid isPermaLink="false">guid_100721464</guid> </item>  <item><title>REUTERS SUMMIT-Faster drug approvals a tonic for pharma industry</title><description><![CDATA[After approvals last year from the FDA for 39 novel medicines- a record only beaten in 1996- the healthy pace has continued into 2013.. And drugmakers are getting further help from a new FDA program to accelerate life-saving therapies designated as a &quot;breakthrough,&quot; opening to door to earlier approval based on quicker studies, where clinical data is compelling.]]></description><link>http://www.cnbc.com/id/100721007</link><pubDate>Wed, 08 May 2013 18:49 GMT</pubDate><guid isPermaLink="false">guid_100721007</guid> </item>  <item><title>Alexza Pharma jumps on Adasuve licensing deal</title><description><![CDATA[NEW YORK-- Shares of Alexza Pharmaceuticals Inc. jumped Wednesday after the company said Teva Pharmaceutical Industries Ltd., one of the world&#039;s largest drug companies, will market is agitation drug Adasuve in the U.S.]]></description><link>http://www.cnbc.com/id/100720781</link><pubDate>Wed, 08 May 2013 17:30 GMT</pubDate><guid isPermaLink="false">guid_100720781</guid> </item>  <item><title>New Data Fans Old Debate About Health Care Costs</title><description><![CDATA[New federal data is putting a new spin on an old debate over health care prices, NBC News reports. ]]></description><link>http://www.cnbc.com/id/100720560</link><pubDate>Wed, 08 May 2013 16:38 GMT</pubDate><guid isPermaLink="false">guid_100720560</guid> </item>  <item><title>Jazz Pharma shares slide despite 1Q profit jump</title><description><![CDATA[Shares of Jazz Pharmaceuticals PLC slid Wednesday morning, a day after the Irish drugmaker said in a regulatory filing that the Food and Drug Administration could approve a competitor&#039;s generic version of its top-seller, narcolepsy treatment Xyrem.]]></description><link>http://www.cnbc.com/id/100720337</link><pubDate>Wed, 08 May 2013 15:31 GMT</pubDate><guid isPermaLink="false">guid_100720337</guid> </item>  <item><title>Get Ready For Hospital 'Sticker Shock'</title><description><![CDATA[For the first time ever, the government is going to release data on what medical care actually costs, reports CNBC&#039;s Hampton Pearson.]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000167006</link><pubDate>Wed, 08 May 2013 15:07 GMT</pubDate><guid isPermaLink="false">guid_100720286</guid> </item>  <item><title>CIA to Starbucks: Where Millennials Want to Work</title><description><![CDATA[Health care and technology, not banking and finance, top millennials&#039; choice of careers, according to a new survey.]]></description><link>http://www.cnbc.com/id/100717637</link><pubDate>Wed, 08 May 2013 14:53 GMT</pubDate><guid isPermaLink="false">guid_100717637</guid> </item>  <item><title>Berkshire Agrees to Limit Stake in DaVita to 25%</title><description><![CDATA[Berkshire Hathaway and dialysis maker DaVita Healthcare entered into an agreement under which Berkshire will not increase its stake above 25 percent. 
 ]]></description><link>http://www.cnbc.com/id/100717804</link><pubDate>Tue, 07 May 2013 21:49 GMT</pubDate><guid isPermaLink="false">guid_100717804</guid> </item>  <item><title>Santarus climbs on 1Q report and new guidance</title><description><![CDATA[NEW YORK-- Shares of Santarus Inc. jumped Tuesday after the biopharmaceutical company posted strong first-quarter results and raised its forecast for the full year. THE SPARK: Santarus reported its quarterly results after the market closed on Monday.]]></description><link>http://www.cnbc.com/id/100717205</link><pubDate>Tue, 07 May 2013 19:31 GMT</pubDate><guid isPermaLink="false">guid_100717205</guid> </item>  <item><title>REUTERS SUMMIT-Biotech firms evolve from targets to acquirers</title><description><![CDATA[*Bankers expect steady flow of $1 bln to $5 bln pharma deals. The stock valuations of companies like Regeneron Pharmaceuticals Inc, Gilead Sciences Inc, Celgene Corp and Biogen Idec Inc have skyrocketed in the past year or two alone, making it difficult for large pharmaceutical companies to buy them and leaving a trail of dead deals.]]></description><link>http://www.cnbc.com/id/100717047</link><pubDate>Tue, 07 May 2013 18:55 GMT</pubDate><guid isPermaLink="false">guid_100717047</guid> </item> </channel>   </rss>